School of Biological Sciences, Georgia Institute of Technology, Atlanta, Georgia, USA
School of Biological Sciences, Georgia Institute of Technology, Atlanta, Georgia, USA.
mBio. 2019 Dec 24;10(6):e02946-19. doi: 10.1128/mBio.02946-19.
To avoid an antibiotic resistance crisis, we need to develop antibiotics at a pace that matches the rate of evolution of resistance. However, the complex functions performed by antibiotics-combining, e.g., penetration of membranes, counteraction of resistance mechanisms, and interaction with molecular targets-have proven hard to achieve with current methods for drug development, including target-based screening and rational design. Here, we argue that we can meet the evolution of resistance in the clinic with evolution of antibiotics in the laboratory. On the basis of the results of experimental evolution studies of microbes in general and antibiotic production in in particular, we propose methodology for evolving antibiotics to circumvent mechanisms of resistance. This exploits the ability of evolution to find solutions to complex problems without a need for design. We review evolutionary theory critical to this approach and argue that it is feasible and has important advantages over current methods for antibiotic discovery.
为避免抗生素耐药性危机,我们需要以与耐药性进化速度相匹配的速度开发抗生素。然而,抗生素所具有的复杂功能——例如,穿透细胞膜、对抗耐药机制以及与分子靶标相互作用——用包括基于靶标筛选和合理设计在内的现有药物开发方法很难实现。在这里,我们认为,我们可以用实验室中抗生素的进化来应对临床中的耐药性进化。根据一般微生物和抗生素生产的实验进化研究的结果,我们提出了一种使抗生素进化以规避耐药机制的方法。这利用了进化在无需设计的情况下找到解决复杂问题的能力。我们回顾了这一方法所必需的进化理论,并认为它是可行的,并且相对于当前的抗生素发现方法具有重要优势。